ProVen Professional – Study – The Cambridge Clostridium Difficile Study

The Cambridge Clostridium difficile Study

Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea

Aim

This randomised, double-blind, placebo controlled study was designed to provide evidence that supplementing with Lab4 probiotics while taking antibiotics can prevent the incidence of antibiotic associated C. difficile diarrhoea (CDAD).

Method

  • The study was carried out at Addenbrooke’s Hospital in Cambridge.
  • 138 elderly patients requiring antibiotic therapy were divided into two equal groups.
  • The first group received 25 billion Lab4 probiotics daily in conjunction with their prescribed antibiotics, for 20 days.
  • The second group took a placebo with their prescribed antibiotics.
  • The efficacy of Lab4 probiotics in the prevention of CDAD was assessed by recording bowel habit and analysing faecal samples.

The results

  • The patient group given Lab4 probiotics experienced a lower incidence of Clostridium difficile diarrhoea compared to the placebo group.
  • This effect was due to a reduction in the presence of the Clostridium difficile toxin in the Lab4 probiotic group.
% of patients positive for Clostridium difficile associated diarrhoea
% of patients positive for Clostridium difficile toxin
Reduction in incidence of symptoms of coughs and colds

Conclusion

Supplementation with Lab4 probiotics can reduce the incidence of C. difficile diarrhoea in hospitalised patients.

Reference

Plummer S et al  2004.
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.
International Microbiology, 7:59-62

proven practitioners
Practitioner Accounts
Get access to our new ProVen Probiotics Practitioner Range
Learn More
null
View More Studies
ProVen Probiotics are supported by a large body of research, which includes both in-vivo and in-vitro trials...
View Studies

Aim

This randomised, double-blind, placebo controlled study was designed to provide evidence that supplementing with Lab4 probiotics while taking antibiotics can prevent the incidence of antibiotic associated C. difficile diarrhoea (CDAD).

Method

  • The study was carried out at Addenbrooke’s Hospital in Cambridge.
  • 138 elderly patients requiring antibiotic therapy were divided into two equal groups.
  • The first group received 25 billion Lab4 probiotics daily in conjunction with their prescribed antibiotics, for 20 days.
  • The second group took a placebo with their prescribed antibiotics.
  • The efficacy of Lab4 probiotics in the prevention of CDAD was assessed by recording bowel habit and analysing faecal samples.

The results

  • The patient group given Lab4 probiotics experienced a lower incidence of Clostridium difficile diarrhoea compared to the placebo group.
  • This effect was due to a reduction in the presence of the Clostridium difficile toxin in the Lab4 probiotic group.
% of patients positive for Clostridium difficile associated diarrhoea
% of patients positive for Clostridium difficile toxin
Reduction in incidence of symptoms of coughs and colds

Conclusion

Supplementation with Lab4 probiotics can reduce the incidence of C. difficile diarrhoea in hospitalised patients.

Reference

Plummer S et al  2004.
Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea.
International Microbiology, 7:59-62

Practitioner Accounts
Get access to our new ProVen Probiotics Practitioner Range
Learn More
View More Studies
ProVen Probiotics are supported by a large body of research, which includes both in-vivo and in-vitro trials...
View Studies